Machine learning operations platform Chief.AI, in partnership with the Medicines Discovery Catapult, has launched the first no-code, pay-as-you-go artificial intelligence (AI) platform for drug discovery. The project is supported by a grant from Innovate UK, and will give small and medium-sized enterprises (SMEs) cloud-based access to AI models and data for drug discovery, diagnostics and clinical trials. Chief.AI's platform is the first no-code service of its type in the bioinformatics space, meaning SMEs can build applications quickly and without substantial internal IT capabilities. The use of AI in drug discovery is growing rapidly, and is expected to transform the pharmaceutical industry more than any other emerging technology. Chief.AI's platform allows SMEs to affordably access cutting-edge technology to minimise the hit-and-miss nature of drug discovery and identify novel therapies with enhanced speed and accuracy, the Manchester-based company said.